BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11120959)

  • 1. Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine.
    Furman PA; Jeffrey J; Kiefer LL; Feng JY; Anderson KS; Borroto-Esoda K; Hill E; Copeland WC; Chu CK; Sommadossi JP; Liberman I; Schinazi RF; Painter GR
    Antimicrob Agents Chemother; 2001 Jan; 45(1):158-65. PubMed ID: 11120959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
    Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs.
    Narayanasamy J; Pullagurla MR; Sharon A; Wang J; Schinazi RF; Chu CK
    Antiviral Res; 2007 Sep; 75(3):198-209. PubMed ID: 17532483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails.
    Mewshaw JP; Myrick FT; Wakefield DA; Hooper BJ; Harris JL; McCreedy B; Borroto-Esoda K
    J Acquir Immune Defic Syndr; 2002 Jan; 29(1):11-20. PubMed ID: 11782585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
    Gu Z; Wainberg MA; Nguyen-Ba N; L'Heureux L; de Muys JM; Bowlin TL; Rando RF
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2376-82. PubMed ID: 10508010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of DApd/DXG against zidovudine- and lamivudine- drug resistant mutants: a molecular modelling approach.
    Chong Y; Borroto-Esoda K; Furman PA; Schinazi RF; Chu CK
    Antivir Chem Chemother; 2002 Mar; 13(2):115-28. PubMed ID: 12238529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys.
    Chen H; Schinazi RF; Rajagopalan P; Gao Z; Chu CK; McClure HM; Boudinot FD
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1625-30. PubMed ID: 10606085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane.
    Gu Z; Wainberg MA; Nguyen-Ba P; L'Heureux L; de Muys JM; Rando RF
    Nucleosides Nucleotides; 1999; 18(4-5):891-2. PubMed ID: 10432704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.
    Jeffrey JL; Feng JY; Qi CC; Anderson KS; Furman PA
    J Biol Chem; 2003 May; 278(21):18971-9. PubMed ID: 12651859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
    Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.
    Feng JY; Myrick F; Selmi B; Deval J; Canard B; Borroto-Esoda K
    Antiviral Res; 2005 Jun; 66(2-3):153-8. PubMed ID: 15885814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
    Seignères B; Pichoud C; Martin P; Furman P; Trépo C; Zoulim F
    Hepatology; 2002 Sep; 36(3):710-22. PubMed ID: 12198665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5'-phosphates by mammalian phosphotransferases.
    Feng JY; Parker WB; Krajewski ML; Deville-Bonne D; Veron M; Krishnan P; Cheng YC; Borroto-Esoda K
    Biochem Pharmacol; 2004 Nov; 68(9):1879-88. PubMed ID: 15450953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients.
    Kewn S; Wang LH; Hoggard PG; Rousseau F; Hart R; MacNeela JP; Khoo SH; Back DJ
    Antimicrob Agents Chemother; 2003 Jan; 47(1):255-61. PubMed ID: 12499199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-performance liquid chromatographic determination of (-)-beta-D-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, using ultraviolet and on-line radiochemical detection.
    Rajagopalan P; Gao Z; Chu CK; Schinazi RF; McClure HM; Boudinot FD
    J Chromatogr B Biomed Appl; 1995 Oct; 672(1):119-24. PubMed ID: 8590923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.
    Tremblay CL; Poulin DL; Hicks JL; Selliah S; Chamberland A; Giguel F; Kollmann CS; Chou TC; Dong H; Hirsch MS
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3644-6. PubMed ID: 14576137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys.
    Chen H; Boudinot FD; Chu CK; Mcclure HM; Schinazi RF
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2332-6. PubMed ID: 8891140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication-dependent 65R-->K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V.
    Sharma PL; Nurpeisov V; Lee K; Skaggs S; Di San Filippo CA; Schinazi RF
    Virology; 2004 Apr; 321(2):222-34. PubMed ID: 15051383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
    Lennerstrand J; Chu CK; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2078-84. PubMed ID: 17403997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short communication cellular pharmacology of 9-(beta-D-1,3-dioxolan-4-yl) guanine and its lack of drug interactions with zidovudine in primary human lymphocytes.
    Hernandez-Santiago BI; Obikhod A; Fromentin E; Hurwitz SJ; Schinazi RF
    Antivir Chem Chemother; 2007; 18(6):343-6. PubMed ID: 18320938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.